• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Waters Corporation (NYSE: WAT) Reports First Quarter 2025 Financial Results

    5/6/25 6:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $WAT alert in real time by email

    Highlights

    • Strong start to the year as first quarter 2025 sales of $662 million landed at the high-end of guidance range; grew 4% as reported and 7% in constant currency
    • Results led by instrument growth of 11% in constant currency, driven by strong momentum in Pharma and Industrial end markets
    • Earnings landed at the high-end of guidance range with GAAP EPS of $2.03 and non-GAAP EPS of $2.25
    • Raising full-year constant currency sales growth guidance to +5.0% to +7.0%, given first quarter strength
    • Raising full-year non-GAAP EPS guidance to the range of $12.75 to $13.05, net of tariff impact, operational actions, and improvement in FX

    First Quarter 2025

    MILFORD, Mass., May 6, 2025 /PRNewswire/ -- Waters Corporation (NYSE: WAT), today announced its financial results for the first quarter of 2025.

    Sales for the first quarter of 2025 were $662 million, an increase of 4% as reported, compared to sales of $637 million for the first quarter of 2024, and an increase of 7% in constant currency.

    On a GAAP basis, diluted earnings per share (EPS) for the first quarter of 2025 was $2.03, compared to $1.72 for the first quarter of 2024. On a non-GAAP basis, EPS was $2.25, representing 2% growth, inclusive of approximately five percentage points of unfavorable foreign exchange.

    "Thanks to the focus and dedication of our teams, the momentum in our business has remained strong despite a very dynamic external environment," said Dr. Udit Batra, President & CEO, Waters Corporation. "Our first-quarter results exceeded expectations, driven by double-digit instrument growth, strength in pharma, and the continued traction of our innovative product portfolio."

    Dr. Batra continued, "Given our unique exposure to resilient, downstream applications and our steadfast commitment to operational excellence, we are raising our full-year 2025 guidance. Our swift operational actions, combined with improvements in foreign exchange, position us well to mitigate the impact of recently announced tariffs and policy changes. As a result, we reaffirm our expectation of delivering high single-digit adjusted EPS growth for the year."

    A description and reconciliation of GAAP to non-GAAP results appear in the tables below and can be found on the Company's website www.waters.com in the Investor Relations section. 

    Full-Year and Second Quarter 2025 Financial Guidance

    Full-Year 2025 Financial Guidance

    The Company is raising its full-year 2025 constant currency sales growth guidance to the range of +5.0% to +7.0%. Net of currency translation, the company is raising its full-year 2025 reported sales growth to the range of +4.0% to +6.0%.

    The Company is raising its full-year 2025 non-GAAP EPS guidance to the range of $12.75 to $13.05. This reflects year-over-year growth of approximately +8% to +10%, and +10% to +12% on a constant currency basis.

    Second Quarter 2025 Financial Guidance

    The Company expects second quarter 2025 constant currency sales growth in the range of +5.0% to +7.0%. Net of currency translation, second quarter 2025 reported sales growth is expected in the range of +4.0% to +6.0%.

    The Company expects second quarter 2025 non-GAAP EPS to be in the range of $2.88 to $2.98, which reflects year-over-year growth of approximately +10% to +13%, and +12% to +15% on a constant currency basis.

    Please refer to the tables below for a reconciliation of the projected GAAP to non-GAAP financial outlook for the full-year and second quarter.

    Conference Call Details

    Waters Corporation will webcast its first quarter 2025 financial results conference call today, May 6, 2025, at 8:00 a.m. Eastern Time. To listen to the call and see the accompanying slide presentation, please visit www.waters.com, select "Investor Relations" under the "About Waters" section, navigate to "Events & Presentations," and click on the "Webcast." A replay will be available through at least June 3, 2025.

    About Waters Corporation

    Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of food and the purity of water, and the quality and sustainability of products used every day. In over 100 countries, our 7,600+ passionate employees collaborate with customers in laboratories, manufacturing sites, and hospitals to accelerate the benefits of pioneering science.

    Non-GAAP Financial Measures

    This press release contains financial measures, such as constant currency growth rates, adjusted operating income, adjusted net income, adjusted earnings per diluted share and free cash flow, among others, which are considered "non-GAAP" financial measures under applicable U.S. Securities and Exchange Commission rules and regulations. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP). The Company's definitions of these non-GAAP measures may differ from similarly titled measures used by others. The non-GAAP financial measures used in this press release adjust for specified items that can be highly variable or difficult to predict. The Company generally uses these non-GAAP financial measures to facilitate management's financial and operational decision-making, including evaluation of the Company's historical operating results, comparison to competitors' operating results and determination of management incentive compensation. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting the Company's business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management strongly encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety. Definitions of the non-GAAP financial measures and reconciliations to the most directly comparable GAAP financial measures are included in the tables accompanying this release.

    Cautionary Statement

    This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "feels", "believes", "anticipates", "plans", "expects", "intends", "suggests", "appears", "estimates", "projects" and similar expressions, whether in the negative or affirmative, are intended to identify forward-looking statements. Our actual future results may differ significantly from the results discussed in the forward- looking statements within this release for a variety of reasons, including and without limitation, risks or uncertainties related to expectations regarding our strategy, our future financial and operational performance, future economic and market conditions, including our expectations about the growth rates of certain markets, our strategic initiatives, including  our instrument replacement initiatives, respond and adapt to changing global dynamics, including the potential impacts of tariffs and supply chain challenges, our ability to retain and attract customers in various geographies and market segments, our market size and growth opportunities, our competitive positioning, projected costs, technological capabilities and plans, and objectives of management. Such factors and others are discussed more fully in the sections entitled "Forward-Looking Statements" and "Risk Factors" of the Company's annual report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission ("SEC"), which discussions are incorporated by reference in this release, as updated by the Company's future filings with the SEC. The forward-looking statements included in this release represent the Company's estimates or views as of the date of this release and should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this release. Except as required by law, the Company does not assume any obligation to update any forward-looking statements.

     

    Waters Corporation and Subsidiaries

    Consolidated Statements of Operations

    (In thousands, except per share data)

    (Unaudited)











    Three Months Ended



    March 29, 2025



    March 30, 2024









    Net sales

    $             661,705



    $             636,839









    Costs and operating expenses:







    Cost of sales

    276,745



    261,786

    Selling and administrative expenses 

    174,881



    174,536

    Research and development expenses 

    46,622



    44,595

    Purchased intangibles amortization 

    11,712



    11,834

    Litigation provision

    -



    10,242









    Operating income 

    151,745



    133,846









    Other income, net

    1,524



    2,259

    Interest expense, net

    (10,381)



    (21,249)









    Income from operations before income taxes

    142,888



    114,856









    Provision for income taxes

    21,507



    12,660









    Net income

    $             121,381



    $             102,196

















    Net income per basic common share

    $                   2.04



    $                   1.73









    Weighted-average number of basic common shares

    59,439



    59,232

















    Net income per diluted common share

    $                   2.03



    $                   1.72









    Weighted-average number of diluted common shares and equivalents

    59,711



    59,431

     

    Waters Corporation and Subsidiaries

    Reconciliation of GAAP to Adjusted Non-GAAP

    Net Sales by Operating Segments, Products & Services, Geography and Markets

    Three Months Ended March 29, 2025 and March 30, 2024

    (In thousands)































































    Constant











    Three Months Ended



    Percent



    Impact of



    Currency











    March 29, 2025



    March 30, 2024



    Change



    Currency



    Growth Rate (a)

































    NET SALES - OPERATING SEGMENTS

























































    Waters





    $

    587,297



    $

    561,899



    5 %



    (3 %)



    8 %

    TA









    74,408





    74,940



    (1 %)



    (1 %)



    1 %

































    Total







    $

    661,705



    $

    636,839



    4 %



    (3 %)



    7 %

































































    NET SALES - PRODUCTS & SERVICES

























































    Instruments





    $

    262,893



    $

    241,944



    9 %



    (3 %)



    11 %

































    Service







    261,175





    260,688



    0 %



    (3 %)



    3 %

    Chemistry







    137,637





    134,207



    3 %



    (3 %)



    5 %

    Total Recurring







    398,812





    394,895



    1 %



    (3 %)



    4 %

































    Total







    $

    661,705



    $

    636,839



    4 %



    (3 %)



    7 %

































































    NET SALES - GEOGRAPHY

























































    Asia







    $

    220,776



    $

    207,559



    6 %



    (6 %)



    13 %

    Americas







    255,537





    241,171



    6 %



    0 %



    6 %

    Europe







    185,392





    188,109



    (1 %)



    (2 %)



    1 %

































    Total







    $

    661,705



    $

    636,839



    4 %



    (3 %)



    7 %

































































    NET SALES - MARKETS

























































    Pharmaceutical





    $

    391,051



    $

    374,207



    5 %



    (3 %)



    8 %

    Industrial







    203,365





    195,334



    4 %



    (2 %)



    6 %

    Academic & Government





    67,289





    67,298



    0 %



    (3 %)



    3 %

































    Total







    $

    661,705



    $

    636,839



    4 %



    (3 %)



    7 %

    ____________________________________

    (a)

    The Company believes that referring to comparable constant currency growth rates is a useful way to evaluate the underlying performance of Waters Corporation's net sales. Constant currency growth, a non-GAAP financial measure, measures the change in net sales between current and prior year periods, excluding the impact of foreign currency exchange rates during the current period. See description of non-GAAP financial measures contained in this release.

     

    Waters Corporation and Subsidiaries

    Reconciliation of GAAP to Adjusted Non-GAAP Financials

    Three Months Ended March 29, 2025 and March 30, 2024

    (In thousands, except per share data)





































































































    Income from



























































    Operations





























    Selling &





    Research &











    Operating











    before





    Provision for











    Diluted











    Administrative





    Development





    Operating





    Income





    Other





    Income





    Income





    Net





    Earnings











    Expenses(a)





    Expenses





    Income





    Percentage





    Income





    Taxes





    Taxes





    Income





    per Share

    Three Months Ended March 29, 2025























































    GAAP





    $

    186,593



    $

    46,622



    $

    151,745





    22.9 %



    $

    1,524



    $

    142,888



    $

    21,507



    $

    121,381



    $

    2.03

    Adjustments:



























































    Purchased intangibles amortization (b)





    (11,712)





    -





    11,712





    1.8 %





    -





    11,712





    2,832





    8,880





    0.15



    Restructuring costs and certain other items (d)





    (598)





    -





    598





    0.1 %





    -





    598





    144





    454





    0.01



    ERP implementation and transformation costs (f)





    (2,295)





    -





    2,295





    0.3 %





    -





    2,295





    551





    1,744





    0.03



    Retention bonus obligation (e)





    (1,909)





    (636)





    2,545





    0.4 %





    -





    2,545





    611





    1,934





    0.03

    Adjusted Non-GAAP



    $

    170,079



    $

    45,986



    $

    168,895





    25.5 %



    $

    1,524



    $

    160,038



    $

    25,645



    $

    134,393



    $

    2.25





























































    Three Months Ended March 30, 2024























































    GAAP





    $

    196,612



    $

    44,595



    $

    133,846





    21.0 %



    $

    2,259



    $

    114,856



    $

    12,660



    $

    102,196



    $

    1.72

    Adjustments:



























































    Purchased intangibles amortization (b)





    (11,834)





    -





    11,834





    1.9 %





    -





    11,834





    2,832





    9,002





    0.15



    Litigation provision (c)





    (10,242)





    -





    10,242





    1.6 %





    -





    10,242





    2,458





    7,784





    0.13



    Restructuring costs and certain other items (d)





    (8,347)





    -





    8,347





    1.3 %





    -





    8,347





    2,055





    6,292





    0.11



    Retention bonus obligation (e)





    (5,725)





    (1,909)





    7,634





    1.2 %





    -





    7,634





    1,832





    5,802





    0.10

    Adjusted Non-GAAP



    $

    160,464



    $

    42,686



    $

    171,903





    27.0 %



    $

    2,259



    $

    152,913



    $

    21,837



    $

    131,076



    $

    2.21

    ____________________________________

    (a)

    Selling & administrative expenses include purchased intangibles amortization and litigation provisions and settlements.

    (b)

    The purchased intangibles amortization, a non-cash expense, was excluded to be consistent with how management evaluates the performance of its core business against historical operating results and the operating results of competitors over periods of time.

    (c)

    Litigation provisions and settlement gains were excluded as these items are isolated, unpredictable and not expected to recur regularly.

    (d)

    Restructuring costs and certain other items were excluded as the Company believes that the cost to consolidate operations, reduce overhead, and certain other income or expense items are not normal and do not represent future ongoing business expenses of a specific function or geographic location of the Company.

    (e)

    In connection with the Wyatt acquisition, the Company started to recognize a two-year retention bonus obligation that is contingent upon the employee's providing future service and continued employment with Waters. The Company believes that these costs are not normal and do not represent future ongoing business expenses.

    (f)

    ERP implementation and transformation costs represent costs related to the Company's initiative to transition from its legacy enterprise resource planning (ERP) system to a new global ERP solution with a cloud-based infrastructure. These costs, which do not represent normal or future ongoing business expenses, are one-time, non-recurring costs related to the establishment of our new global ERP solution that were determined to be non-capitalizable in accordance with accounting standards.

     

    Waters Corporation and Subsidiaries

    Preliminary Condensed Unclassified Consolidated Balance Sheets

    (In thousands and unaudited)



























    March 29, 2025



    December 31, 2024

















    Cash and cash equivalents





    $              382,872



    $              325,355

    Accounts receivable







    713,278



    733,365

    Inventories







    511,499



    477,261

    Property, plant and equipment, net



    643,260



    651,200

    Intangible assets, net







    560,754



    567,906

    Goodwill









    1,300,020



    1,295,720

    Other assets







    479,893



    502,988

       Total assets







    $           4,591,576



    $           4,553,795

































    Notes payable and debt





    $           1,456,727



    $           1,626,488

    Other liabilities







    1,172,452



    1,098,800

       Total liabilities







    2,629,179



    2,725,288

















    Total stockholders' equity





    1,962,397



    1,828,507

       Total liabilities and stockholders' equity



    $           4,591,576



    $           4,553,795

     

    Waters Corporation and Subsidiaries

    Preliminary Condensed Consolidated Statements of Cash Flows

    Three Months Ended March 29, 2025 and March 30, 2024

    (In thousands and unaudited)























    Three Months Ended









    March 29, 2025



    March 30, 2024











    Cash flows from operating activities:









    Net income

    $                    121,381



    $                 102,196



    Adjustments to reconcile net income to net













    cash provided by operating activities:











    Stock-based compensation

    12,878



    10,913





    Depreciation and amortization

    49,369



    48,514





    Change in operating assets and liabilities and other, net

    75,925



    101,247







    Net cash provided by operating activities

    259,553



    262,870















    Cash flows from investing activities:









    Additions to property, plant, equipment













    and software capitalization

    (25,742)



    (28,655)



    Investments in unaffiliated companies

    (506)



    (1,064)



    Net change in investments

    -



    (25)







    Net cash used in investing activities

    (26,248)



    (29,744)















    Cash flows from financing activities:









    Net change in debt

    (170,000)



    (300,000)



    Proceeds from stock plans

    8,246



    13,932



    Purchases of treasury shares

    (13,934)



    (13,089)



    Other cash flow from financing activities, net

    2,441



    6,981







    Net cash used in financing activities

    (173,247)



    (292,176)















    Effect of exchange rate changes on cash and cash equivalents

    (2,541)



    1,264







    Increase (decrease) in cash and cash equivalents

    57,517



    (57,786)















    Cash and cash equivalents at beginning of period

    325,355



    395,076







    Cash and cash equivalents at end of period

    $                    382,872



    $                 337,290















    Reconciliation of GAAP Cash Flows from Operating Activities to Free Cash Flow (a)















    Net cash provided by operating activities - GAAP

    $                    259,553



    $                 262,870

















    Adjustments:











    Additions to property, plant, equipment













    and software capitalization

    (25,742)



    (28,655)





    Litigation settlements received, net

    -



    (375)

    Free Cash Flow - Adjusted Non-GAAP

    $                    233,811



    $                 233,840

    ____________________________________

    (a)

    The Company defines free cash flow as net cash flow from operations accounted for under GAAP less capital expenditures and software capitalizations plus or minus any unusual and non recurring items. Free cash flow is not a GAAP measurement and may not be comparable to free cash flow reported by other companies.

     

    Waters Corporation and Subsidiaries

    Reconciliation of Projected GAAP to Adjusted Non-GAAP Financial Outlook



























    Twelve Months Ended



    Three Months Ended







    December 31, 2025



    June 28, 2025









    Range







    Range



    Projected Sales



































    Constant currency sales growth rate (a)

    5.0 %

    -

    7.0 %



    5.0 %

    -

    7.0 %

    Currency translation impact

    (1.0 %)

    -

    (1.0 %)



    (1.0 %)

    -

    (1.0 %)

    Sales growth rate as reported

    4.0 %

    -

    6.0 %



    4.0 %

    -

    6.0 %





























    Range







    Range



    Projected Earnings Per Diluted Share



































    GAAP earnings per diluted share

    $    11.88

    -

    $    12.18



    $      2.66

    -

    $      2.76

    Adjustments:



















    Purchased intangibles amortization 

    $      0.60

    -

    $      0.60



    $      0.15

    -

    $      0.15



    ERP implementation and transformation costs 

    $      0.22

    -

    $      0.22



    $      0.05

    -

    $      0.05



    Retention bonus obligation

    $      0.05

    -

    $      0.05



    $      0.02

    -

    $      0.02

    Adjusted non-GAAP earnings per diluted share

    $    12.75

    -

    $    13.05



    $      2.88

    -

    $      2.98

    ____________________________________

    (a)

    Constant currency growth rates are a non-GAAP financial measure that measures the change in net sales between current and prior year periods, excluding the impact of foreign currency exchange rates during the current period. These amounts are estimated at the current foreign currency exchange rates and based on the forecasted geographical sales in local currency, as well as an assessment of market conditions as of today, and may differ significantly from actual results.



    These forward-looking adjustment estimates do not reflect future gains and charges that are inherently difficult to predict and estimate due to their unknown timing, effect and/or significance.

     

    Contact:  Caspar Tudor, Head of Investor Relations – (508) 482-2429

    Cision View original content:https://www.prnewswire.com/news-releases/waters-corporation-nyse-wat-reports-first-quarter-2025-financial-results-302446356.html

    SOURCE Waters Corporation

    Get the next $WAT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $WAT

    DatePrice TargetRatingAnalyst
    3/31/2025$460.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/26/2025$396.00 → $407.00Neutral → Outperform
    Robert W. Baird
    2/13/2025$450.00Sector Perform → Sector Outperform
    Scotiabank
    2/10/2025$360.00 → $415.00Underweight → Equal Weight
    Barclays
    1/10/2025$430.00Mkt Perform → Outperform
    Bernstein
    12/23/2024Sector Perform
    Scotiabank
    10/8/2024$355.00 → $415.00Hold → Buy
    Jefferies
    8/28/2024$380.00Overweight
    Wells Fargo
    More analyst ratings

    $WAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Fearon Richard H bought $332,900 worth of shares (1,000 units at $332.90), increasing direct ownership by 153% to 1,653 units (SEC Form 4)

      4 - WATERS CORP /DE/ (0001000697) (Issuer)

      5/29/24 11:23:35 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP TA Instruments Division Bennett Jianqing covered exercise/tax liability with 303 shares, decreasing direct ownership by 6% to 4,916 units (SEC Form 4)

      4 - WATERS CORP /DE/ (0001000697) (Issuer)

      4/8/25 5:43:17 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Jiang Wei was granted 53 shares, increasing direct ownership by 2% to 2,410 units (SEC Form 4)

      4 - WATERS CORP /DE/ (0001000697) (Issuer)

      4/2/25 5:12:56 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Knight Heather was granted 53 shares, increasing direct ownership by 9% to 613 units (SEC Form 4)

      4 - WATERS CORP /DE/ (0001000697) (Issuer)

      4/2/25 5:11:33 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    Financials

    Live finance-specific insights

    See more
    • Waters Corporation (NYSE: WAT) Reports First Quarter 2025 Financial Results

      Highlights Strong start to the year as first quarter 2025 sales of $662 million landed at the high-end of guidance range; grew 4% as reported and 7% in constant currencyResults led by instrument growth of 11% in constant currency, driven by strong momentum in Pharma and Industrial end marketsEarnings landed at the high-end of guidance range with GAAP EPS of $2.03 and non-GAAP EPS of $2.25Raising full-year constant currency sales growth guidance to +5.0% to +7.0%, given first quarter strengthRaising full-year non-GAAP EPS guidance to the range of $12.75 to $13.05, net of tariff impact, operational actions, and improvement in FXFirst Quarter 2025 MILFORD, Mass., May 6, 2025 /PRNewswire/ -- Wat

      5/6/25 6:00:00 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance
    • Waters Corporation Schedules First Quarter 2025 Earnings Conference Call

      MILFORD, Mass., April 8, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q1 2025 financial results conference call on Tuesday, May 6th, 2025 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least June 3rd, 2025, at midnight Eastern Time. About Waters Corporation  Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of food

      4/8/25 4:30:00 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Waters Integrates Multi-Angle Light Scattering Detectors with Empower Software for Improved Biologics Quality Control and Simplified Regulatory Compliance

      News Summary  Saves up to six months on compliant software validation in biopharmaceutical quality control.1Reduces analysis time for biotherapeutic peptides and proteins by 20%.2Enhances quality control by providing absolute molecular weight of biologics and avoiding common errors encountered with other techniques.3MILFORD, Mass., May 6, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that its Empower™ Software now supports biologics data acquisition and quality control (QC) analysis from Multi-Angle Light Scattering (MALS) and differential Refractive Index (RI) instruments in its Wyatt Technology™ Portfolio. This integration expands the scope of critical quality attribut

      5/6/25 6:15:00 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters Corporation (NYSE: WAT) Reports First Quarter 2025 Financial Results

      Highlights Strong start to the year as first quarter 2025 sales of $662 million landed at the high-end of guidance range; grew 4% as reported and 7% in constant currencyResults led by instrument growth of 11% in constant currency, driven by strong momentum in Pharma and Industrial end marketsEarnings landed at the high-end of guidance range with GAAP EPS of $2.03 and non-GAAP EPS of $2.25Raising full-year constant currency sales growth guidance to +5.0% to +7.0%, given first quarter strengthRaising full-year non-GAAP EPS guidance to the range of $12.75 to $13.05, net of tariff impact, operational actions, and improvement in FXFirst Quarter 2025 MILFORD, Mass., May 6, 2025 /PRNewswire/ -- Wat

      5/6/25 6:00:00 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance

    $WAT
    Leadership Updates

    Live Leadership Updates

    See more

    $WAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $WAT
    SEC Filings

    See more
    • Waters Corporation Appoints Heather Knight to Board of Directors

      MILFORD, Mass., Aug. 14, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the appointment of Heather Knight to its Board of Directors effective August 14, 2024. Ms. Knight currently serves as Executive Vice President and Group President, Medical Products and Therapies at Baxter International. Heather is an accomplished leader who brings decades of experience across the pharma and medical device industries."Heather is an accomplished leader who brings decades of experience across the pharmaceutical and medical device industries, with a proven track record for

      8/14/24 4:15:00 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters Corporation Appoints Richard Fearon to Board of Directors

      Waters™ Corporation (NYSE:WAT) today announced the appointment of Richard Fearon to its Board of Directors, effective March 27, 2023. Mr. Fearon is the former Vice Chairman and Chief Financial and Planning Officer of Eaton Corporation, a multinational power management company. "Rick's expertise is at the intersection of financial excellence, strategic development and transformation, which are the key pillars of Waters' growth plan. We are confident that Rick's unique skillset will complement our Board well and we look forward to benefiting from his insights as we continue to drive value for shareholders," said Dr. Flemming Ornskov, Chairman of the Board. Dr. Udit Batra, CEO and President,

      3/28/23 8:00:00 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters Corporation Appoints Dan Brennan and Mark Vergnano to Board of Directors

      Waters Corporation (NYSE:WAT) today announced the appointment of Dan Brennan and Mark Vergnano, to its Board of Directors, effective November 23, 2022. Mr. Brennan currently serves as Executive Vice President and Chief Financial Officer of Boston Scientific Corporation, a global medical device company, and Mr. Vergnano is the former Chairman, President and Chief Executive Officer of The Chemours Company, a chemistry company. "Dan and Mark are outstanding leaders whose decades of experience in the medical device and chemistry industries will add tremendous value as Waters continues to execute its exciting growth strategy," said Dr. Flemming Ornskov, Chairman of the Board. "These appointment

      11/23/22 8:00:00 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters upgraded by KeyBanc Capital Markets with a new price target

      KeyBanc Capital Markets upgraded Waters from Sector Weight to Overweight and set a new price target of $460.00

      3/31/25 7:57:55 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters upgraded by Robert W. Baird with a new price target

      Robert W. Baird upgraded Waters from Neutral to Outperform and set a new price target of $407.00 from $396.00 previously

      3/26/25 7:47:54 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters upgraded by Scotiabank with a new price target

      Scotiabank upgraded Waters from Sector Perform to Sector Outperform and set a new price target of $450.00

      2/13/25 8:14:37 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 10-Q filed by Waters Corporation

      10-Q - WATERS CORP /DE/ (0001000697) (Filer)

      5/6/25 7:00:36 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters Corporation filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - WATERS CORP /DE/ (0001000697) (Filer)

      5/6/25 6:05:51 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEFA14A filed by Waters Corporation

      DEFA14A - WATERS CORP /DE/ (0001000697) (Filer)

      4/9/25 4:16:58 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Waters Corporation

      SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

      11/12/24 11:54:03 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Waters Corporation (Amendment)

      SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

      2/14/24 9:37:22 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Waters Corporation (Amendment)

      SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

      2/13/24 5:17:31 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials